Various medical shops have been telling buyers that the medicine is in short supply but can be made available If they are ready to pay a premium, DCGI has been informed

A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug

Cipla's net profit during the March quarter of FY20 took a beating on account of the coronavirus pandemic. The company posted a 33 per cent decline in consolidated net profit during the quarter ended March 2020

Stocks to watch today on April 29: Axis Bank, Atul, JK Paper, NLC India, L&T, PNB Housing, Biocon, Thomas Cook among others are the top stocks to watch out for in Wednesday's trading session

Experts believe there was already a visible turnaround in the pharma sector, both on the domestic as well as on the exports side even before any traces of COVID-19

True North will invest Rs 536.25 crore for a 2.44 per cent minority stake in Biocon Biologics India, taking its value to Rs 21,450 crore, or around $3 billion

Biosimilars are a different ball game -- more complex and more expensive, essentially because biotech drugs, by their very nature, require understanding of living organisms

Ogivri will be launched at a competitive discount for customers to help ensure increased access to treatment for thousands of HER2-positive breast and gastric cancer patients, said Biocon

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

The significant violations included failure to have adequate written procedures for the receipt, identification, testing and handling of raw materials

According to Biocon Biologics CEO Christiane Hamacher, the high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide

Despite no big product launches in the US last year, Natco Pharma gained from its strategy of focussing on a few big products. It now hopes to build on this.

Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.

Strides Pharma Science attributes its underwhelming performance to a confluence of headwinds and execution challenges.

Enbrel had global brand sales of approximately $11.6 billion for the 12 months ending December 31, 2017, according to IQVIA.

By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.